| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Oligodendrocyte transcription factor 2;Oligo2;Class B basic helix-loop-helix protein 1;bHLHb1;Class E basic helix-loop-helix protein 19;bHLHe19;Protein kinase C-binding protein 2;Protein kinase C-binding protein RACK17;OLIG2;BHLHB1, BHLHE19, PRKCBP2, RACK17; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Form | Liquid |
| Host | |
| Immunogen | A synthesized peptide derived from human FOLR1 |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Storage | |
| Target | |
| UniProt # |
Overview
This product is an anti-FOLR1 antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone 17F59; isotype IgG; reactivity: Human,Mouse,Rat. Reported application contexts include WB (as provided in the source record). Boster Bio Anti-FOLR1 Rabbit Monoclonal Antibody catalog # M02254. Tested in WB application. This antibody reacts with Human, Mouse, Rat.
Key elements and design rationale
- Target: FOLR1 (Oligodendrocyte transcription factor 2).
- Antibody format: Monoclonal; clone 17F59; isotype IgG.
- Host: Rabbit.
- Species reactivity: Human,Mouse,Rat (confirm in your model system with appropriate controls).
This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.
Biological background
FOLR1 (protein: Lysosome-associated membrane glycoprotein 2 (Lamp2)) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Required for oligodendrocyte and motor neuron specification in the spinal cord, as well as for the development of somatic motor neurons in the hindbrain. Cooperates with OLIG1 to establish the pMN domain of the embryonic neural tube. Antagonist of V2 interneuron and of NKX2-2-induced V3 interneuron development (By similarity). . Reported cellular localization context: Nucleus . Cytoplasm . The NLS contained in the bHLH domain could be masked in the native form and translocation to the nucleus could be mediated by interaction either with class E bHLH partner protein or with NKX2-2. . Tissue expression notes (as provided): Expressed in the brain, in oligodendrocytes. Strongly expressed in oligodendrogliomas, while expression is weak to moderate in astrocytomas. Expression in glioblastomas highly variable. .
Research relevance and current trends
- Research context keywords from the source record include: Transcription Factors.
- Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
- Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.
Common research applications
- Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
Workflow ideas (metafield): Validate FOLR1 antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect FOLR1 expression by Western blot in cell or tissue lysates, Compare relative FOLR1 levels across experimental conditions (dose/time-course) using antibody-based readouts
Notes for experimental interpretation
- Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
- Apparent molecular weight may vary by sample type and processing (observed MW: 117 kDa; calculated MW: 32385 MW).
- Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.
Additional product details (from the source record)
- Molecular weight (observed): 117 kDa
- Cellular localization (provided): Nucleus . Cytoplasm . The NLS contained in the bHLH domain could be masked in the native form and translocation to the nucleus could be mediated by interaction either with class E bHLH partner protein or with NKX2-2. .
- Tissue details (provided): Expressed in the brain, in oligodendrocytes. Strongly expressed in oligodendrogliomas, while expression is weak to moderate in astrocytomas. Expression in glioblastomas highly variable. .
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
